REGN) ? It's down huge for the year and it's a great company." A.O. Smith Corp …
The stock had its biggest gain on record ... Aimmune Therapeutics Inc. and Regeneron Pharmaceuticals Inc. are working together to develop a treatment for peanut allergies. Aimmune plans to release initial results from a late-stage trial of its …
As such, the analyst reiterates a Neutral rating on REGN stock without listing a …
The stock decreased 0.31% or $1.03 during the last trading session, reaching $332.15. About 1.18 million shares traded …
Click to Enlarge On the daily time frame, Regeneron stock exhibited an incredible rally during the past few days — one that began with a bullish hammer candle on Feb. 5 when the broader market showed a similar development. Click to …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
After posting better-than-expected first-quarter results, Regeneron Pharmaceuticals (NASDAQ: REGN) stock enjoyed a nice bounce. The biotech announced solid sales for eye-disease drug Eylea and a strong launch for atopic dermatitis …
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) stock has been a huge winner in the past. A $10,000 investment in the biotech 10 years ago would be worth more than $200,000 today. Regeneron's shareholders have been on a roller …
Regeneron Pharmaceuticals Inc ( REGN) stock is down 25% this year, and that's after a near 12.5% gain last Friday. Those gains came after Regeneron announced positive Phase-3 data on a treatment for moderate-to-severe atopic …